Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | ATF4 | P18848 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 4/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499449 | 1.00 | NR1H4 (0.36) | NR1H4ATF4TRPV3HDAC4HDAC6 | |
| SCHEMBL22614229 | 0.86 | HDAC4 (0.36) | ATF4TRPV3HDAC4TRPA1 | |
| SCHEMBL29499478 | 0.84 | NR1H4 (0.36) | NR1H4ATF4HDAC4HDAC6TRPA1 | |
| SCHEMBL29408904 | 0.84 | NR1H4 (0.36) | NR1H4ATF4HDAC4HDAC6TRPA1 | |
| SCHEMBL29408894 | 0.83 | POLB (0.41) | CHRM1 | |
| SCHEMBL29409025 | 0.81 | CNR2 (0.39) | ATF4CHRM1IDO1 | |
| SCHEMBL29409171 | 0.78 | GSK3B (0.37) | ATF4TRPA1IDO1GPR119 | |
| SCHEMBL29499492 | 0.78 | GSK3B (0.37) | ATF4TRPA1IDO1GPR119 | |
| SCHEMBL29499484 | 0.74 | GSK3B (0.35) | ATF4HDAC4TRPA1IDO1GPR119 | |
| SCHEMBL29409098 | 0.74 | GSK3B (0.35) | ATF4HDAC4TRPA1IDO1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962906-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NR1H4 548/4885ATF4 1/4885TRPV3 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.